Clinical Trial Update: Nebulized Fentanyl in Patients With Mild to Moderate Interstitial Lung Disease and Chronic Dyspnea [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating nebulized fentanyl for dyspnea in patients with mild to moderate interstitial lung disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease

Drugs mentioned

• Nebulized fentanyl (fentanyl)

Snippet

Sponsor: Dr. Denis O'Donnell | Conditions: Interstitial Lung Disease | Phase 3 | Status: COMPLETED